Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Brief description of study

Blood is an easily accessible source of tumor cell free (cf) DNA. Both normal and malignant cells shed DNA into the circulation, and advanced genomics technologies can analyze tumor cfDNA, making blood a source of real-time genomic tumor profiling. For ccRCC patients, peripheral blood will be obtained as part of routine clinical care. Blood will be collected at baseline, first restaging scan, second restaging scan and at time of progression or approximately 2 years, whichever occurs first.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 08 Jun 2022. Study ID: 849801

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).